Top Qs
Timeline
Chat
Perspective
Tabernanthalog
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
Tabernanthalog (TBG; developmental code name DLX-007) is a non-selective serotonin receptor modulator and putatively non-psychedelic psychoplastogen of the ibogalog group related to the iboga alkaloid tabernanthine but with a simplified chemical structure.[2][3] It was developed by David E. Olson and colleagues at the University of California, Davis.[3] The drug is being developed by Delix Therapeutics as a potential pharmaceutical drug for treatment of neuropsychiatric disorders.[1][4]
Remove ads
Use and effects
There have been informal anecdotal reports of the effects of tabernanthalog.[5][6][7] It is said to be psychoactive and mildly hallucinogenic at sufficiently high doses and to have a long duration.[6] Its hallucinogenic effects have been said to be similar to but weaker than those of serotonergic psychedelics.[6][7] There were also reports of side effects like nausea, dizziness, stomach discomfort, and diarrhea.[6][7] However, it is unclear whether the reports have always employed actual tabernanthalog.[6]
Remove ads
Interactions
Pharmacology
Summarize
Perspective
Pharmacodynamics
Tabernanthalog is a non-selective and non-psychedelic serotonin receptor modulator, including acting as an agonist of the serotonin 5-HT1B, 5-HT1F, 5-HT2A, 5-HT2C, and 5-HT6 receptors and as an agonist or antagonist of the serotonin 5-HT2B receptor.[3][8][10] It also shows significant binding to the serotonin transporter (SERT) (acting as a serotonin reuptake inhibitor), the α2A-adrenergic receptor, and monoamine oxidase A (MAO-A).[3] In contrast to iboga alkaloids like ibogaine and noribogaine, tabernanthalog showed negligible interactions with opioid receptors, the NMDA receptor, and certain nicotinic acetylcholine receptors.[3] However, in subsequent research, it weakly inhibited certain nicotinic acetylcholine receptors, as well as, to a much lesser extent, the GABAA receptor.[12] Tabernanthalog was found to be 100-fold less potent at the hERG antitarget compared to ibogaine, and hence is thought to have a much lower potential for cardiotoxicity.[3]
Tabernanthalog did not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence appears to be non-hallucinogenic.[3] However, it was found to promote structural neuroplasticity (i.e., to act as a psychoplastogen), reduce drug-seeking behavior, and produce antidepressant-like effects.[3][13][14][15] It has also been shown that it reduces motivation for heroin and alcohol in rodents.[15]
Remove ads
History
Tabernanthalog was first described in the scientific literature by David E. Olson and colleagues at the University of California, Davis in January 2021.[3][16]
Society and culture
Grey market use
Tabernanthalog has been known to be sold online by research chemical vendors for purposes such as "nootropic" use.[6]
Research
Tabernanthalog is under development for the treatment of central nervous system disorders (CNS disorders).[1][17] It is being developed by Delix Therapeutics.[1][17] As of May 2025, no recent development has been reported.[1] It had reached the preclinical research stage of development.[1][17] A phase 1 clinical trial was being planned for the first half of 2023.[1] Delix Therapeutics also partnered with National Institute on Drug Abuse (NIDA) to evaluate tabernanthalog for the treatment of substance-related disorders in December 2021.[1]
Remove ads
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads